Comparative Pharmacology
Head-to-head clinical analysis: PONVORY versus TASCENSO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONVORY versus TASCENSO ODT.
PONVORY vs TASCENSO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, inducing internalization and degradation of the receptor, thereby preventing egress of lymphocytes from lymph nodes, reducing peripheral lymphocyte count and immune-mediated demyelination in the central nervous system.
0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.
14 mg orally once daily, with or without food. Swallow whole; do not crush, chew, or dissolve.
None Documented
None Documented
Terminal half-life is approximately 11 days (range 8-15 days), supporting once-daily dosing with steady-state reached in about 6-8 weeks.
Terminal elimination half-life is 48-56 hours, supporting once-daily dosing.
Primarily metabolized via CYP3A4; elimination mainly as metabolites in feces (85-90%) and urine (<1% unchanged).
Renal: ~80% unchanged; biliary/fecal: ~20% as metabolites.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator